

IN THE SPECIFICATION:

Please replace the paragraphs beginning at page 6, line 12 to page 8, line 4 with the following paragraphs. Appendix A provides "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

The following provides sequences of some individual antigens used in the compositions and fusion proteins of the invention:

MTB32A (TbRa35FL) (SEQ ID NOS:3 and 4 of the present application), the sequence of which is disclosed as SEQ ID NO:17 (cDNA) and SEQ ID NO:79 (protein) in the U.S. patent application No. 08/659,683 and is also disclosed in U.S. patent applications No. 08/523,436, 08/523,435, No. 08/658,800, No. 08/818,112, No. 09/056,556, and No. 08/818,111 and in the WO97/09428 and WO97/09429 publications, *see also* Skeiky *et al.*, *Infection and Immunity* 67:3998-4007 (1999);

MTBRa12, the C-terminus of MTB32A (Ra35FL) (SEQ ID NOS:5 and 6 of the present application), comprising at least about the last 132 amino acids from MTB32A from *M. tuberculosis*, the sequence of which is disclosed as SEQ ID NO:4 (DNA) and SEQ ID NO:66 (predicted amino acid sequence) in the U.S. patent application No. 09/072,967;

Ra35, the N-terminus of MTB32A (Ra35FL), comprising at least about the first 205 amino acids of MTB32A from *M. tuberculosis*, the nucleotide and amino acid sequence of which is disclosed in Figure 4 (SEQ ID NOS:1 and 2 of the present application);

MTB39 (TbH9) (SEQ ID NOS:7 and 8 of the present application), the sequence of which is disclosed as SEQ ID NO:106 (cDNA full length) and SEQ ID NO:107 (protein full length) in the U.S. patent application No. 08/659,683 and is also disclosed in U.S. patent applications No. 08/658,800, No. 08/818,112, and No. 08/818,111 and in the WO97/09428 and WO97/09429 publications. The sequence is also disclosed as SEQ ID NO:33 (DNA) and SEQ ID NO:91 (amino acid) in U.S. patent application No. 09/056,556 (SEQ ID NOS:25 and 26 of the present application).

The following provides sequences of some fusion proteins of the invention:

TbH9-Ra35 (MTB59F) (SEQ ID NOS:9 and 10 of the present application), the sequence of which is disclosed as SEQ ID NO:23 (cDNA) and SEQ ID NO:24 (protein) in the U.S. patent application No. 09/287,849 as originally filed and in the PCT/US99/07717 application;

RA12-TbH9-Ra35 (MTB72F) (SEQ ID NOS:11 and 12 of the present application), the sequence of which is disclosed as SEQ ID NO:1 (DNA) and SEQ ID NO:2 (protein) in the US patent application No. 09/223,040, and in the PCT/US99/07717 application.

The following provides sequences of some additional antigens used in the compositions and fusion proteins of the invention:

MTB8.4 (DPV) (SEQ ID NOS:13 and 14 of the present application), the sequence of which is disclosed as SEQ ID NO:101 (cDNA) and SEQ ID NO:102 (protein) in the U.S. patent application No. 08/659,683 and is also disclosed in U.S. patent applications No. 08/658,800, No. 08/818,112 and No. 08/818,111 and in the WO97/09428 and WO97/09429 publications;

MTB9.8 (MSL) (SEQ ID NOS:15 and 16 of the present application), the sequence of which is disclosed as SEQ ID NO:12 (DNA), SEQ ID NO:109 (predicted amino acid sequence) and SEQ ID NO:110 to 124 (peptides) in the U.S. patent application No. 09/073,010 and is also disclosed in U.S. patent applications No. 08/859,381, No. 08/858,998 and No. 09/073,009 and in the PCT/US98/10407 and PCT/US98/10514 applications;

MTB9.9A (MTI, also known as MTI-A) (SEQ ID NOS:17 and 18 of the present application), the sequence of which is disclosed as SEQ ID NO:3 and SEQ ID NO:4 (DNA) and SEQ ID NO:29 and SEQ ID NO:51 to 66 (ORF peptide for MTI) in the U.S. patent application No. 09/073,010 and is also disclosed in U.S. patent applications No. 08/859,381, No. 08/858,998 and No. 09/073,009 and in the PCT/US98/10407 and

PCT/US98/10514 applications. Two other MTI variants also exist, called MTI-B and MTI-C;

MTB40 (HTCC#1) (SEQ ID NOS:19 and 20 of the present application), the sequence of which is disclosed as SEQ ID NO:137 (cDNA) and 138 (predicted amino acid sequence) in the U.S. patent application No. 09/073,010 and is also disclosed in U.S. patent application No. 09/073,009 and in the PCT/US98/10407 and PCT/US98/10514 applications;

MTB41 (MTCC#2) (SEQ ID NOS:21 and 22 of the present application), the sequence of which is disclosed as SEQ ID NO:140 (cDNA) and SEQ ID NO:142 (predicted amino acid sequence) in the U.S. patent application No. 09/073,010 and is also disclosed in U.S. patent application No. 09/073,009 and in the PCT/US98/10407 and PCT/US98/10514 applications;

ESAT-6 (SEQ ID NOS:23 and 24 of the present application), the sequence of which is disclosed as SEQ ID NO:103 (DNA) and SEQ ID NO:104 (predicted amino acid sequence) in the U.S. patent application No. 09/072,967. The sequence of ESAT-6 is also disclosed in U.S. Patent No. 5,955,077;

α -crystalline antigen (SEQ ID NOS:27 and 28), the sequence of which is disclosed in Verbon *et al.*, *J. Bact.* 174:1352-1359 (1992);

85 complex antigen (SEQ ID NOS:29 and 30), the sequence of which is disclosed in Content *et al.*, *Infect. & Immunol.* 59:3205-3212 (1991).--

Please cancel the present "SEQUENCE LISTING", pages 1-3, submitted July 30, 2001, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 23, at the end of the application.